�St. Jude Medical, Inc. (NYSE:STJ) proclaimed U.S. Food and Drug Administration (FDA) and European CE Mark approvals of EonC�, the first extended-life primary cellphone (non-rechargeable) neurostimulator for the treatment of chronic nuisance.
The EonC neurostimulator provides a convenient option for chronic pain sensation patients wHO prefer or require the simplicity of a non-rechargeable medical device. Featuring the greatest battery capacity of any primary cell neurostimulator, the EonC may maximise the time between device replacement procedures.
"Selecting the right system for each patient is vital for the winner of spinal anesthesia cord stimulation (SCS) therapy," said Chris Chavez, president of the St. Jude Medical ANS Division. "With chronic pain in the ass, there's no such affair as a 'one size of it fits all' approach. For some patients, a non-rechargeable device like EonC provides the perfect solution for their of necessity."
The EonC system's patient benefits let in:
- Proprietary engineering (called NeuroDynamix�) which helps deliver stimulation with greater efficiency
- Advanced programming capability which allows patients to adjust therapy strength in up to eight infliction areas at the same time and independently
- Constant electric current circuitry which automatically adjusts power output to deliver consistent therapy over time
- High mightiness and high pulse frequencies which enable clinicians to adjust the therapy to accommodate single patient needs
EonC is the only 16-contact, constant current, non-rechargeable system for SCS therapy. With the addition of EonC to its product portfolio, ANS now provides an even more comprehensive line of SCS devices to meet the of necessity of chronic pain patients. The new device complements Eon�, a high-capacity, rechargeable device, and Eon Mini�, the world's smallest, longest-lasting rechargeable neurostimulator.
Neurostimulators like EonC are designed to provide SCS therapy to treat complex neuropathic pain sensation of the trunk and limbs or pain from failed back surgeries. Similar in function and appearance to cardiac pacemakers, these devices drive home mild electric pulses to the spinal anaesthesia cord, interrupting or covering the bother signals' contagion to the brain. More than 35,000 patients in 35 countries feature been deep-rooted with St. Jude Medical neurostimulation systems. Patients throne obtain more information about neurostimulation hurting therapies at http://www.PowerOverYourPain.com.
Pain is a serious and costly world health result, and it remains for the most part under-treated and misunderstood. According to the National Institutes of Health, 90 trillion people in the U.S. suffer from chronic hurting. The American Pain Foundation estimates that chronic botheration costs around $100 one thousand million per year in lost work time and health care expenses.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putt more ascendency into the hands of those world Health Organization treat cardiac, neurological and chronic painful sensation patients world. The company is consecrate to forward-moving the practice of practice of medicine by reduction risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,500 people world-wide and has five major focus areas that include: cardiac regular recurrence management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.http://www.sjm.com
About the ANS Division of St. Jude Medical
The ANS Division (Advanced Neuromodulation Systems) became part of St. Jude Medical in 2005. The ANS Division is an innovative engineering science leader consecrated to the design, development, manufacturing and marketing of implantable neuromodulation systems to improve the quality of life for people hurt from disabling chronic hurting and other nervous organisation disorders hTTP://www.ans-medical.com.
Forward-Looking Statements
This news release contains innovative statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such advanced statements include the expectations, plans and prospects for the Company, including potentiality clinical successes, anticipated regulative approvals and future product launches, and projected revenues, margins, salary, and market shares. The statements made by the Company ar based upon management's current expectations and are depicted object to sure risks and uncertainties that could lawsuit actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include securities industry conditions and other factors beyond the Company's dominance and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K filed on February 27, 2008. The Company does not intend to update these statements and undertakes no duty to any person to bring home the bacon any such update under any circumstance.
St. Jude Medical
More info
